1. Silver sucrose octasulfate nasal applications and wound healing after endoscopic sinus surgery: a prospective, randomized, double-blind, placebo-controlled study.
- Author
-
Ottaviano G, Blandamura S, Fasanaro E, Favaretto N, Andrea L, Giacomelli L, Bartolini A, Staffieri C, Marchese-Ragona R, Marioni G, and Staffieri A
- Subjects
- Administration, Intranasal, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Ulcer Agents administration & dosage, Biopsy, Chronic Disease, Double-Blind Method, Ethmoid Sinusitis complications, Ethmoid Sinusitis pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nasal Mucosa drug effects, Nasal Mucosa pathology, Prospective Studies, Rhinitis complications, Rhinitis pathology, Sucrose administration & dosage, Young Adult, Endoscopy methods, Ethmoid Sinusitis surgery, Otorhinolaryngologic Surgical Procedures methods, Postoperative Care methods, Rhinitis surgery, Sucrose analogs & derivatives, Wound Healing drug effects
- Abstract
Objectives: The aim of the present prospective, randomized, double-blind, and placebo-controlled investigation (approved by the Ethical Committee of Padova University Hospital [Italy]) was to assess the effect of a nasal gel containing a combination of silver sucrose octasulfate and potassium sucrose octasulfate (Silsos gel® [SG]) in wound healing after endoscopic sinus surgery (ESS) for chronic rhinosinusitis in terms of: nasal symptoms (SNOT22), endoscopic appearance of the sinonasal mucosa (Lund-Kennedy score), nasal air flow (anterior active rhinomanometry), evidence of mucosal inflammatory processes (nasal cytology and histology), and microbiological growth., Methods: Thirty-four patients with chronic rhinosinusitis were randomized on a 1:1 ratio to receive after ESS either SG or placebo (contained only the excipients [carbopol and propylene glycol] in the same concentrations as in SG)., Results/conclusions: Judging from the present prospective investigation on patients who underwent ESS for chronic rhinosinusitis, treatment with SG seems to enable a significantly faster improvement in specific symptoms (assessed on the validated SNOT22 scale) than placebo. Patients treated with SG also had a quicker improvement in the endoscopic appearance of their nasal mucosa after ESS than patients treated with placebo. These endoscopic improvements in the SG group were also confirmed at the long-term follow-up, while the same did not apply to the placebo-treated group., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF